The novel tubulin-binding 'tumor checkpoint controller' BAL101553 has anti-cancer activity alone and in combination treatments across a panel of GBM patient-derived xenografts

被引：2
|
作者：
Mladek, Ann C.
Pokorny, Jenny L.
Lane, Heidi
Bachmann, Felix
Schroeder, Mark A.
Bakken, Katrina K.
Carlson, Brett L.
Decker, Paul A.
Eckel-Passow, Jeanette E.
Sarkaria, Jann N.
机构：
来源：
CANCER RESEARCH | 2016年 / 76卷
关键词：
D O I：
10.1158/1538-7445.AM2016-4781
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4781
引用
收藏
页数：4
相关论文
共 2 条
  • [1] The novel tubulin-binding, tumor checkpoint controller BAL101553 has differential effects on tumor vascularization with IV and oral dosing and provides superior anti-tumor activity in combination with bevacizumab
    Sharma, Ashish
    Bachmann, Felix
    Broggini-Tenzer, Angela
    Guckenberger, Matthias
    Lane, Heidi
    Pruschy, Martin N.
    CANCER RESEARCH, 2017, 77
  • [2] THE ANTIBODY-DRUG CONJUGATE ABT-414 DEMONSTRATES SINGLE-AGENT ANTI-CANCER ACTIVITY ACROSS A PANEL OF GBM PATIENT-DERIVED XENOGRAFTS
    Marin, Bianca
    Mladek, Ann
    Burgenske, Danielle
    He, Lihong
    Hu, Zeng
    Bakken, Katrina
    Carlson, Brett
    Schroeder, Mark
    Sarkaria, Jann
    NEURO-ONCOLOGY, 2018, 20 : 69 - 69
1